Immunocure is a preclinical drug discovery CRO, that leverages an in-house generative AI-based discovery platform – AxDrug integrated with computational chemistry tools and synthetic chemistry lab to create best-in-class lead candidates for our clients.
DRUG DISCOVERY CRO

SMALL MOLECULE DISCOVERY
IN SILICO / IN VITRO
AI & Computational chemistry services for Target validation, Hit identification, Hit to Lead identification & Lead optimization

DRUG DEVELOPMENT
IN SILICO
AI powered Drug Development services including Pre-formulations, Formulation optimization, and Drug- delivery systems

COSMETICS DEVELOPMENT
IN SILICO / IN VITRO
Cosmetics design and development : Finding new Cosmetics and Topical formulations using in-house AI models and computational tools



THE ADVANTAGE
Immunocure team understands the system at an atomic level with their pattern of interactions using computational methods and converts them into properties. These properties can then be explored using machine learning and/or deep learning tools thus converting them into knowledge/hypothesis.
Ideation, automation, prediction, optimization, toxicity, and attrition are the key factors controlling Drug Discovery, Drug Development / Formulations, and Agrochemicals. They can be comprehensively addressed with the derived knowledge/hypothesis. Thus, Immunocure automates the Drug Discovery, Drug Development, and Deployment Map using AI and computational chemistry methods (Computer-Aided Drug Design Models (CADD) / MoMo).
Our Drug Discovery team has strong computational chemistry and AI expertise. The major advantage is having an experienced R&D team having extensive experience in drug discovery using computational chemistry. We can understand the problem by leveraging advanced technologies of computational chemistry and AI for innovative solutions with a high hit rate in less time and thus reducing research and development (R&D) costs for our clients.
DRUG DISCOVERY WORKFLOW
Our Recent Publications
- Identification of SARS-CoV-2 Main Protease Inhibitors Using Structure Based Virtual Screening and Molecular Dynamics Simulation of DrugBank Database
- In silico analysis and identification of promising hits against 2019 novel coronavirus 3C-like main protease enzyme